Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.

Tamagno G, Sheahan K, Skehan SJ, Geoghegan JG, Fennelly D, Collins CD, Maguire D, Traynor O, Brophy DP, Cantwell C, Swan N, McGowan L, O'Toole D, O'Shea D.

Endocrine. 2013 Oct;44(2):504-9. doi: 10.1007/s12020-013-9910-5. Epub 2013 Mar 8.

PMID:
23471696
2.
3.

[Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].

Holzer K.

Chirurg. 2014 Aug;85(8):731-44. doi: 10.1007/s00104-013-2679-5. Review. German.

PMID:
25103842
4.

Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.

Zhang X, Ma L, Bao H, Zhang J, Wang Z, Gong P.

BMC Endocr Disord. 2014 Jul 8;14:54. doi: 10.1186/1472-6823-14-54.

5.

Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.

Sclafani F, Carnaghi C, Di Tommaso L, Rodari M, Destro A, Rimassa L, Giordano L, Chiti A, Roncalli M, Santoro A.

Tumori. 2011 Sep-Oct;97(5):620-8. doi: 10.1700/989.10722.

6.

Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.

Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A.

J Endocrinol Invest. 2012 Oct;35(9):817-23. doi: 10.3275/8102. Epub 2011 Nov 9.

PMID:
22080849
7.

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

de Herder WW.

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):689-90. doi: 10.1016/j.bpg.2013.01.005. No abstract available.

PMID:
23582912
8.

Multidisciplinary approach for the treatment of neuroendocrine tumors.

de Herder WW, Mazzaferro V, Tavecchio L, Wiedenmann B.

Tumori. 2010 Sep-Oct;96(5):833-46. No abstract available.

PMID:
21302641
9.

Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs).

Orgera G, Krokidis M, Cappucci M, Gourtsoyianni S, Tipaldi MA, Hatzidakis A, Rebonato A, Rossi M.

Cardiovasc Intervent Radiol. 2015 Feb;38(1):13-24. doi: 10.1007/s00270-014-1005-z. Epub 2014 Nov 5. Review.

PMID:
25366087
10.

Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.

Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM.

World J Gastroenterol. 2013 Dec 21;19(47):9012-9. doi: 10.3748/wjg.v19.i47.9012.

11.

[Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors)].

Kos-Kudła B, Bolanowski M, Handkiewicz-Junak D, Jarzab B, Królicki L, Krzakowski M, Kunikowska J, Nasierowska-Guttmejer A, Nowak A, Rydzewska G, Starzyńska T, Szawłowski A; oraz Pozostali Uczestnicy Konferencji Okragłego Stołu.

Endokrynol Pol. 2008 Jan-Feb;59(1):41-56. Polish.

PMID:
18335400
12.

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A.

J Nucl Med. 2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16.

13.
14.

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Öberg K, Knigge U, Kwekkeboom D, Perren A; ESMO Guidelines Working Group.

Ann Oncol. 2012 Oct;23 Suppl 7:vii124-30. No abstract available.

15.

Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.

Du S, Ni J, Weng L, Ma F, Li S, Wang W, Sang X, Lu X, Zhong S, Mao Y.

Medicine (Baltimore). 2015 Aug;94(34):e1429. doi: 10.1097/MD.0000000000001429.

16.

[Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].

Wang X, Song ZF, Yao WX, Pan CC, Xiang MF, Wang H.

Zhonghua Yi Xue Za Zhi. 2013 May 14;93(18):1411-4. Chinese.

PMID:
24025507
17.

Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.

Garcia-Carbonero R.

Cancer Metastasis Rev. 2014 Mar;33(1):343-4. doi: 10.1007/s10555-013-9469-x. No abstract available.

PMID:
24357057
18.

[Contemporary methods of diagnosis and treatment of neuroendocrine gastrointestinal tumors].

Kos-Kudła B, Zemczak A.

Endokrynol Pol. 2006 Mar-Apr;57(2):174-86. Review. Polish.

PMID:
16773594
19.

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R.

Ann Oncol. 2010 Sep;21(9):1794-803. doi: 10.1093/annonc/mdq022. Epub 2010 Feb 5. Review.

20.

[Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital].

Alvarado-Cabrero I, de Anda-González J, Hernández-Hernández B, Mantilla-Morales A, Valencia-Cedillo R, Medrano-Guzmán R.

Rev Gastroenterol Mex. 2012 Oct-Dec;77(4):174-80. doi: 10.1016/j.rgmx.2012.08.003. Epub 2012 Nov 9. Spanish.

Items per page

Supplemental Content

Write to the Help Desk